48
Participants
Start Date
February 17, 2022
Primary Completion Date
December 31, 2025
Study Completion Date
January 31, 2026
JAB-21822
JAB-21822 administered orally as a tablet.
Cetuximab
Cetuximab administered as an intravenous (IV) infusion.
Research site31, Beijing
Research site01, Beijing
Research site02, Beijing
Research site12, Beijing
Research site06, Harbin
Research site28, Shanghai
Research site09, Nanjing
Research site16, Linyi
Research site19, Hangzhou
Research site08, Nanchang
Research site11, Changsha
Research site29, Changsha
Research site18, Wuhan
Research site05, Zhengzhou
Research site07, Zhengzhou
Research site13, Nanning
Research site23, Xi’an
Lead Sponsor
Allist Pharmaceuticals, Inc.
INDUSTRY